Advanced ALK-Positive Lung Cancer Treatment with LuciAle (Alectinib) Tablets

As precision oncology continues to reshape cancer care worldwide, LuciAle (Alectinib) Tablets by Cordium Pharmaceuticals Pvt Ltd has emerged as a trusted targeted therapy for patients diagnosed with ALK-positive Non-Small Cell Lung Cancer (NSCLC).

LuciAle is designed to help oncologists deliver effective, personalized treatment that targets cancer cells while helping patients maintain a better quality of life.

Cordium Pharmaceuticals proudly supports hospitals, oncology centers, distributors, importers, and healthcare partners across Kenya, Nigeria, Ghana, Philippines, Vietnam, UAE, Saudi Arabia, Uzbekistan, Kazakhstan, USA, UK, and South Africa.

What is LuciAle (Alectinib)?

LuciAle contains Alectinib, a next-generation ALK inhibitor used to treat adults diagnosed with ALK-positive metastatic Non-Small Cell Lung Cancer (NSCLC).

This targeted therapy works by blocking abnormal ALK proteins that drive the growth and spread of cancer cells.

Unlike conventional chemotherapy, Alectinib specifically targets cancer-causing pathways.

Key Treatment Areas:

✔ ALK-positive metastatic NSCLC

✔ Advanced lung cancer

✔ Lung cancer with brain metastases

✔ First-line targeted lung cancer treatment

Why is Alectinib Transforming Lung Cancer Treatment Worldwide?

Cancer specialists globally are increasingly recommending Alectinib because of its proven clinical benefits.

Benefits of LuciAle (Alectinib) Tablets

Enhanced Brain Protection

Alectinib effectively reaches the brain and helps manage cancer spread to the central nervous system.

Longer Disease Control

Patients may experience delayed disease progression compared to earlier treatment options.

Precision Targeting

The medicine selectively blocks ALK-positive cancer cells.

Improved Patient Convenience

Oral tablet administration eliminates the need for frequent intravenous chemotherapy sessions.

Better Treatment Tolerability

Many patients experience manageable side effects under physician supervision.

How Does LuciAle Work?

Some lung cancer patients have an abnormal ALK gene fusion that causes uncontrolled cell growth.

LuciAle helps by:

• Blocking ALK signaling pathways
• Slowing tumor growth
• Reducing cancer spread
• Controlling brain metastases
• Supporting long-term disease management

This personalized treatment approach has become an important advancement in modern oncology.

Who May Benefit From LuciAle?

LuciAle may be considered for:

• Adults diagnosed with ALK-positive NSCLC
• Patients requiring first-line targeted therapy
• Patients with metastatic lung cancer
• Patients with brain metastases
• Patients transitioning from older ALK inhibitor therapies

Treatment suitability should always be determined by a qualified oncologist.

Common Side Effects

Patients may experience:

• Fatigue
• Constipation
• Muscle aches
• Swelling in hands and feet
• Elevated liver enzymes
• Weight gain
• Reduced red blood cell count

Regular monitoring is essential throughout treatment.

Why Healthcare Professionals Choose Cordium Pharmaceuticals Pvt Ltd

Cordium Pharmaceuticals is dedicated to improving access to affordable, high-quality oncology medicines worldwide.

Our Global Strengths

✅ Reliable pharmaceutical exporter

✅ International supply capabilities

✅ Quality-driven manufacturing standards

✅ Regulatory documentation support

✅ Efficient logistics management

✅ Strong distributor partnerships

✅ Sustainable oncology supply chain

Countries We Serve

Cordium Pharmaceuticals supports healthcare organizations in:

Africa

🇰🇪 Kenya

🇳🇬 Nigeria

🇬🇭 Ghana

🇿🇦 South Africa

Southeast Asia

🇵🇭 Philippines

🇻🇳 Vietnam

Middle East

🇦🇪 UAE

🇸🇦 Saudi Arabia

Central Asia

🇺🇿 Uzbekistan

🇰🇿 Kazakhstan

Western Markets

🇺🇸 USA

🇬🇧 UK

Why LuciAle is Gaining Global Demand in 2026

The rising adoption of molecular testing and precision oncology has increased the demand for targeted therapies like Alectinib.

Healthcare providers are actively searching for:

• Affordable Alectinib suppliers
• Trusted oncology medicine exporters
• Reliable NSCLC treatment providers
• International pharmaceutical partners
• High-quality ALK inhibitor manufacturers

Cordium Pharmaceuticals is committed to meeting this growing demand.